News & Events Archives - Page 5 of 15

Liver Fibrosis Scores as Predictors of Long-term Outcomes in Patients with ST-segment Elevation Myocardial Infarction

Announcing a new article publication for Cardiovascular Innovations and Applications journal.

Liver fibrosis scores (LFSs) are novel tools for predicting cardiovascular events in patients with coronary artery disease. This study was aimed at examining the prognostic value of LFSs in patients with ST-segment elevation myocardial infarction (STEMI).

Between 2015 and 2019, 866 patients diagnosed with STEMI were consecutively enrolled. The definition of major cardiovascular events (MACEs) was all-cause death, nonfatal myocardial infarction, nonfatal ischemic stroke, and acute limb ischemia. The authors of this article evaluated the predictive values of LFSs for MACEs with receiver operating characteristic (ROC) curve and restricted cubic spline (RCS) analysis. Kaplan-Meier (K-M) analysis was conducted to explore the relationship between LFSs and MACEs.

During a median follow-up of 4 years, 155 MACEs were observed. K-M analysis of MACEs revealed significantly lower event-free survival rates in patients with intermediate or high, rather than low, NFS, FIB-4, BARD, and Forns scores. The multivariable-adjusted hazard ratios (95% CI) for MACEs in patients with high versus low risk scores were 1.343 (0.822–2.197) for NFS, 1.922 (1.085–3.405) for FIB-4, 2.395 (1.115–5.142) for BARD, and 2.271 (1.250–4.125) for Forns. The ROC curve indicated that the predictive ability for MACEs was non significantly improved by addition of the NFS (AUC = 0.7274), FIB-4 (AUC = 0.7199), BARD (AUC = 0.7235), and Forns (AUC = 0.7376) scores into the basic model (AUC = 0.7181). RCS revealed a tendency toward a nonlinear positive association of MACEs with NFS, FIB-4, and particularly Forns scores.

LFSs have potential utility for predicting adverse outcomes in patients with STEMI, thus indicating the importance of managing metabolic dysregulation.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0095

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Longyang Zhu, Yinong Chen and Qing Li et al. Liver Fibrosis Scores as Predictors of Long-term Outcomes in Patients with ST-segment Elevation Myocardial Infarction. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2023.0095

Rapid Plaque Progression in a Patient with Non-ST-Segment Elevation Acute Coronary Syndrome

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Acute coronary syndrome (ACS), diagnosed by optical coherence tomography (OCT), is caused primarily by plaque rupture, plaque erosion, and calcified nodules. Plaque erosion is more common in patients with non-ST-segment elevation myocardial infarction than ST-segment elevation myocardial infarction. This study reports the details of a case of ACS caused by massive thrombus formation due to plaque erosion. The factors associated with plaque erosion and thrombosis could not be confirmed on the basis of clinical examination findings and the physicians’ experience; therefore, the initial diagnosis of an ischemic event was replaced by a diagnosis of rapid plaque progression, as microscopically confirmed by OCT. Therefore, OCT examination must be performed for blurred or “rapidly progressing” lesions identified through angiography.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0081

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Yachao Li et al. Rapid Plaque Progression in a Patient with Non-ST-Segment Elevation Acute Coronary Syndrome. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2023.0081

Clinical Significance of PCSK9 and Soluble P-selectin in Predicting Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study aimed at investigating the association of proprotein convertase subtilisin/kexin type 9 (PCSK9) with soluble P-selectin (sP-selectin), and their values in predicting major adverse cardiovascular events (MACE) at 1-year follow-up in patients with acute coronary syndrome (ACS) receiving dual antiplatelet therapy after primary percutaneous coronary intervention (PCI).

A total of 563 patients with ACS who underwent primary PCI were prospectively recruited from March 2020 to June 2021. The baseline levels of PCSK9, sP-selectin, and other platelet reactivity biomarkers were determined using enzyme-linked immunosorbent assays.

sP-selectin and ox-LDL levels significantly increased with increasing PCSK9 tertiles. High sP-selectin was associated with high PCSK9 levels, and PCSK9 was positively correlated with sP-selectin. Patients with both PCSK9 >17.4 ng/mL and sP-selectin >7.2 ng/mL had a significantly higher incidence of MACE than patients with lower levels. Multivariate analysis indicated that high sP-selectin and PCSK9 levels were independent risk factors for MACE, and the combination of PCSK9 and sP-selectin had better predictive value than each biomarker alone.

PCSK9 and sP-selectin may be potential predictive biomarkers for 1-year prognosis in patients with ACS after primary PCI.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0087

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Yao Yao, Qining Qiu and Xiaoye Li et al. Clinical Significance of PCSK9 and Soluble P-selectin in Predicting Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2023.0087

Risk-Predictive Models for Adverse Events in Cardiac Surgery: A Review

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Risk prediction models are an important part of assessing operative mortality and postoperative complication rates in current cardiac surgery practice. Furthermore, they guide clinical decision-making and perioperative patient management. In recent years, a variety of clinical prediction models have been developed in China and other countries to assess the risk of mortality and complications after cardiac surgery. Currently, the most widely used and mature models are the new version of the European Cardiac Surgery Evaluation System (EuroSCORE II), the American Society of Thoracic Surgeons Cardiac Surgery Risk Model (STS score), and the Chinese Coronary Artery Bypass Graft Surgery Risk Evaluation System (SinoSCORE). This article reviews the application of these three risk prediction models, to identify the optimal model for guiding clinical practice.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0083

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Huan Luo. Risk-Predictive Models for Adverse Events in Cardiac Surgery: A Review. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2023.0083

Associations of Heart Failure Onset Age with All-Cause Mortality: The Kailuan Study

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study was aimed at investigating the correlations between heart failure onset age and all-cause mortality.

The study examined 186,249 patients treated at Kailuan Group hospitals who underwent medical evaluations between 2006 and 2018. Biennial health assessments were conducted, and, as of December 31, 2020, 4022 heart failure instances were identified. For each patient with new-onset heart failure, four control participants were randomly selected, matched for age (within ±1 year) and sex. Cox regression models were used to calculate the hazard ratios of all-cause mortality across age groups.

The median follow-up duration was 5.25 (2.65, 8.63) years. All-cause mortality occurred in 1783 participants in the new-onset heart failure group and 2633 participants in in the control group. Refined multivariable Cox regression analysis revealed that patients with heart failure under 55 years of age had the highest relative mortality risk, with an HR (95% CI) 6.86 (4.42–10.64) with respect to their matched controls. Moreover, the relative mortality risk systematically decreased with increasing age of heart failure onset: HR (95% CI) 4.70 (3.73–5.92) for ages 55–64, HR (95% CI) 3.23 (3.73–3.81) for ages 65–74, and HR (95% CI) 1.69 (1.48–1.94) for 75 years or older.

Heart failure significantly elevates the risk of all-cause mortality, and the risk is more pronounced with earlier manifestation of the condition.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0085

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Wei Li, Haibo Gao and Xuemei Zhao et al. Associations of Heart Failure Onset Age with All-Cause Mortality: The Kailuan Study. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2023.0085

Incremental Metabolic Benefits from Cryoablation for Paroxysmal Atrial Fibrillation: Insights from Metabolomic Profiling

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Cryoablation (CRYO) is a novel catheter ablation technique for atrial fibrillation (AF). However, uncertainty persists regarding the role of metabolic modifications associated with CRYO. This study was aimed at exploring whether CRYO influences the metabolic signature – a possibility not previously investigated.

Paired serum samples from patients with AF (n = 10) were collected before and 24 h after CRYO. Untargeted metabolomic analysis was conducted with LC-MS. Univariate and multivariate analyses were applied to identify differential metabolites between samples. Pathway enrichment and Pearson correlation analyses were performed to reveal the perturbed metabolic pathways and potential interactions.

Levels of 19 metabolites showed significant changes between baseline and 24 h after CRYO. Pathway analysis revealed that the perturbed metabolites were enriched in unsaturated fatty acid biosynthesis, retrograde endocannabinoid signaling, and neuroactive ligand-receptor interactions. Pearson correlation analysis indicated strong correlations among differential metabolites, biochemical markers, and clinical indicators.

CRYO induces systemic changes in the serum metabolome in patients with paroxysmal AF and provides potential metabolic benefits. These findings might enable enhanced understanding of the pathophysiology and metabolic mechanisms involved in catheter ablation.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0079

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Mengjie Xie, Fuding Guo and Jun Wang et al. Incremental Metabolic Benefits from Cryoablation for Paroxysmal Atrial Fibrillation: Insights from Metabolomic Profiling. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2023.0079

Atrial Fibrillation Follow-up Investigation to Recover Memory and Learning Trial (AFFIRMING): Rationale and Design of a Multi-center, Double-blind, Randomized Controlled Trial

Announcing a new article publication for Cardiovascular Innovations and Applications journal. People with atrial fibrillation (AF) have elevated risk of developing cognitive impairment. At present, there is a dearth of randomized controlled trials investigating cognitive impairment management in patients with AF. The Atrial Fibrillation Follow-up Investigation to Recover Memory and learning (AFFIRMING) study is aimed at evaluating the potential for computerized cognitive training to improve cognitive function in patients with AF.

This study is a multi-center, double-blind, randomized controlled study using a 1:1 parallel design. A total of 200 patients with AF and mild cognitive decline without dementia are planned to be recruited. The intervention group will use the adaptive training software with changes in difficulty, whereas the positive control group will use basic training software with minimal or no variation in difficulty level. At the end of 12 weeks, the participants will be unblinded, and the positive control group will stop training. The intervention group will be rerandomized 1:1 to stop training or continue training. All participants will be followed up until 24 weeks. The primary endpoint is the proportion of the improvement of the global cognitive function at week 12 compared with baseline, using the Basic Cognitive Ability Test (BCAT).

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0080

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Zhiyan Wang, Yiqun Zhang and Chao Jiang et al. Atrial Fibrillation Follow-up Investigation to Recover Memory and Learning Trial (AFFIRMING): Rationale and Design of a Multi-center, Double-blind, Randomized Controlled Trial. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2023.0080

Successful TAVI Despite Sudden Low Output and Ventricular Fibrillation in a Patient with Cardiac Amyloidosis

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Management of patients with cardiac amyloidosis and concomitant high-grade aortic stenosis is challenging. This article reports the case of a 79-year-old man with transcatheter aortic valve implantation (TAVI) complicated by low cardiac output during release of a Medtronic Evolut R 34 mm valve. After initiation of mechanical circulatory support, the TAVI valve was successfully implanted despite ongoing ventricular fibrillation. The ventricular fibrillation was successfully treated with injection of potassium into the aorta, with subsequent defibrillation and ventricular pacing. Moreover, pharmacological management of transient severe LV dysfunction and high-grade mitral regurgitation finally led to a favourable course.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0078

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Peter Ong, Stephan Hill and Dominik Bierbaum et al. Successful TAVI Despite Sudden Low Output and Ventricular Fibrillation in a Patient with Cardiac Amyloidosis. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0078

Research Progress in Heart Rate Variability Applications in Exercise Rehabilitation for Cardiovascular Diseases

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Heart rate variability (HRV) is an important marker for assessing the balance of the autonomic nervous system and clinical prognosis, because it can be non-invasively and easily measured, and the results are accurate and valuable. HRV is widely applied in cardiovascular disease fields. Exercise training is an important part of cardiac rehabilitation. Personalized sports rehabilitation therapy can effectively prevent the emergence of cardiovascular diseases, decrease the risk of recurrent cardiovascular events, and ameliorate dysfunction, as well as limitations in life, work, and social participation, caused by adverse cardiovascular events. However, sports rehabilitation can have drawbacks, in that improper training can cause injury, excessive fatigue, or even harmful cardiovascular events. To support future applications, this article reviews recent applications of HRV in sports rehabilitation for cardiovascular diseases.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0071

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Zhaoxin Zhu, Jianying Shen and Yan Zhang et al. Research Progress in Heart Rate Variability Applications in Exercise Rehabilitation for Cardiovascular Diseases. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0071

Heart Failure Guideline Directed Medical Therapy: Which One and When?

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Over the past several decades, major strides have been made in the management of heart failure with reduced ejection fraction (HFrEF). The 2022 AHA/ACC/HFSA guidelines recommend four drug classes in all patients with symptomatic HFrEF. This guideline directed therapy (GDMT) includes renin angiotensin receptor (RAAS) blockade, preferentially with angiotensin receptor neprilysin inhibitors (ARNI), beta blockers, mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter inhibitors (SGLT2i). An optimal GDMT regimen has been estimated to achieve greater than 70% mortality benefit. Unfortunately, most patients with HFrEF are not taking the appropriate medications or doses. Several clinical challenges and questions arise when attempting to initiate and titrate these medications. Although the guidelines offer several suggestions for this process, each patient’s hemodynamic profile varies markedly, thus making development of a uniform algorithm difficult. As new trials are performed, greater emphasis is being placed on more aggressive titration of GDMT. Most importantly, initiation of GDMT should start during hospitalization and continue with close outpatient follow-up. Identifying each patient profile, defined by volume status, blood pressure, heart rate, and kidney function, dictates the order and timing of GDMT titration.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0077

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Michelle Dimza and Juan M. Aranda. Heart Failure Guideline Directed Medical Therapy: Which One and When?. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0077

CVIA Journal

Category: News & Events